[go: up one dir, main page]

IL133869A0 - Novel composition novel formulations comprising an ssri in combination with a beta blocker - Google Patents

Novel composition novel formulations comprising an ssri in combination with a beta blocker

Info

Publication number
IL133869A0
IL133869A0 IL13386998A IL13386998A IL133869A0 IL 133869 A0 IL133869 A0 IL 133869A0 IL 13386998 A IL13386998 A IL 13386998A IL 13386998 A IL13386998 A IL 13386998A IL 133869 A0 IL133869 A0 IL 133869A0
Authority
IL
Israel
Prior art keywords
novel
ssri
combination
beta blocker
formulations
Prior art date
Application number
IL13386998A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc Smithkl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc Smithkl filed Critical Smithkline Beecham Plc Smithkl
Publication of IL133869A0 publication Critical patent/IL133869A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL13386998A 1997-07-11 1998-07-07 Novel composition novel formulations comprising an ssri in combination with a beta blocker IL133869A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition
PCT/EP1998/004971 WO1999002142A2 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker

Publications (1)

Publication Number Publication Date
IL133869A0 true IL133869A0 (en) 2001-04-30

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13386998A IL133869A0 (en) 1997-07-11 1998-07-07 Novel composition novel formulations comprising an ssri in combination with a beta blocker

Country Status (26)

Country Link
EP (1) EP0996466A2 (zh)
JP (1) JP2002508003A (zh)
KR (1) KR20010021644A (zh)
CN (1) CN1262627A (zh)
AP (1) AP2000001728A0 (zh)
AR (1) AR016128A1 (zh)
AU (1) AU9340198A (zh)
BG (1) BG104119A (zh)
BR (1) BR9810996A (zh)
CA (1) CA2295822A1 (zh)
CO (1) CO4950552A1 (zh)
DZ (1) DZ2556A1 (zh)
EA (1) EA200000112A1 (zh)
GB (1) GB9714675D0 (zh)
HU (1) HUP0003074A3 (zh)
ID (1) ID24191A (zh)
IL (1) IL133869A0 (zh)
MA (1) MA24604A1 (zh)
NO (1) NO20000107D0 (zh)
OA (1) OA11276A (zh)
PE (1) PE99699A1 (zh)
PL (1) PL338017A1 (zh)
SK (1) SK72000A3 (zh)
TR (1) TR200000074T2 (zh)
WO (1) WO1999002142A2 (zh)
ZA (1) ZA986138B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
NZ511442A (en) 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1793818A2 (en) * 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
GB9714675D0 (en) 1997-09-17
NO20000107L (no) 2000-01-10
JP2002508003A (ja) 2002-03-12
CA2295822A1 (en) 1999-01-21
OA11276A (en) 2003-07-31
AU9340198A (en) 1999-02-08
WO1999002142A2 (en) 1999-01-21
ID24191A (id) 2000-07-13
CO4950552A1 (es) 2000-09-01
HUP0003074A2 (hu) 2001-01-29
MA24604A1 (fr) 1999-04-01
WO1999002142A3 (en) 1999-04-15
HUP0003074A3 (en) 2001-12-28
BR9810996A (pt) 2000-08-08
AR016128A1 (es) 2001-06-20
PE99699A1 (es) 1999-12-21
KR20010021644A (ko) 2001-03-15
NO20000107D0 (no) 2000-01-10
DZ2556A1 (fr) 2003-02-15
AP2000001728A0 (en) 2000-03-31
EA200000112A1 (ru) 2000-10-30
CN1262627A (zh) 2000-08-09
BG104119A (en) 2000-12-29
PL338017A1 (en) 2000-09-25
SK72000A3 (en) 2000-12-11
ZA986138B (en) 2000-01-10
TR200000074T2 (tr) 2000-05-22
EP0996466A2 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
EG20753A (en) Synergistic composition
HK1017854A1 (en) Oral composition
PL340255A1 (en) Non-dissolving insulin compositions
GB9414721D0 (en) Dentifrice composition
EP0965321A4 (en) COMPOSITION FOR EXTERNAL USE
GB9704524D0 (en) Composition
GB9715203D0 (en) Composition
GB9713620D0 (en) Composition
HUP0004064A3 (en) Dentrifice composition
IL133869A0 (en) Novel composition novel formulations comprising an ssri in combination with a beta blocker
ZA982863B (en) Synergistic fungicadal composition
GB9715489D0 (en) Composition
GB9714010D0 (en) Composition
GB9701031D0 (en) Composition
GB9714359D0 (en) Composition
GB9726284D0 (en) Composition
GB9605067D0 (en) Enamel composition
GB9618964D0 (en) Oral composition
GB9826467D0 (en) Composition
GB9724975D0 (en) Composition
SG63838A1 (en) Oral composition
GB9705110D0 (en) Composition
EG23068A (en) Pesticidale composition
ZA986892B (en) Bread improving composition
GB9719592D0 (en) Composition